February 17, 2026. The date the hounds started baying. 4D Advisors, those meticulous vultures, just unloaded 110,000 shares of U.S. Physical Therapy. A cool $9.34 million evaporated into the ether. They say a watched pot never boils. Well, this pot boiled over and scalded somebody. And it wasn’t the market makers.
The Exit Strategy (or Lack Thereof)
Let’s be blunt. This wasn’t a trim. This was a full-scale, get-the-hell-out-of-Dodge evacuation. USPH. The stock’s been circling the drain, a slow, agonizing spiral. While the S&P is scaling Everest, these guys are digging a hole. A $9.34 million exit isn’t a vote of confidence, it’s a flare gun shot into the pre-dawn darkness. A warning. A desperate plea. Or maybe just a cold, calculated move by a firm that smells trouble brewing.
Where Did the Money Go?
4D’s new affections, as of late, are…interesting. They’re piling into TPB (NYSE: $12.47 million – 6.8% of AUM). CWST (NASDAQ: $9.30 million – 5.1% AUM). FSS (NYSE: $7.60 million – 4.2% AUM). AXON (NASDAQ: $7.10 million – 3.9% AUM). And FICO (NYSE: $6.76 million – 3.7% AUM). Waste services, data-driven businesses, and…consumer stuff. The usual suspects when the market gets jittery. A flight to relative safety. USPH? Left to rot. As of the 17th, USPH was clinging to $86.54, up a pathetic 0.2% over the last year. A rounding error in the grand scheme of things. A statistical anomaly. A phantom limb.
The Numbers. Cold. Hard. Numbers.
| Metric | Value |
|---|---|
| Price (February 17, 2026) | $86.54 |
| Market Capitalization | $1.3 billion |
| Revenue (TTM) | $758.7 million |
| Net Income (TTM) | $36.0 million |
The Company Line. (Don’t Believe a Word Of It)
Outpatient physical therapy. Industrial injury prevention. Ergonomic assessments. Performance optimization. Sounds…sanitizing. Sterile. Like a hospital ward for broken dreams. They serve everyone, apparently. Fortune 500 companies. Insurers. Contractors. The usual suspects. Diversified, they call it. I call it spreading the misery. A dual-segment strategy? More like a two-headed monster. Recurring revenue? Recurring nightmares, more like it.
What Does This Mean For You? (If You’re Still Listening)
Healthcare services are supposed to be…reliable. Steady. A slow, grinding march towards profitability. But USPH? Flatlined. Stalled. The kind of underperformance that sends investors scrambling for the exits. Revenue is up, sure. Gross profit is up. But earnings? That’s where the rot sets in. The last earnings release sent shares tumbling 12%. Twelve percent! In this market! That’s a bloodbath. And CEO Chris Reading is babbling about acquisitions and hospital relationships. Empty promises. Smoke and mirrors. A desperate attempt to distract from the inevitable. The stock is still underperforming. Still. And that, my friends, is the bottom line. A cold, hard, terrifying truth.
Read More
- Top 20 Dinosaur Movies, Ranked
- 20 Movies Where the Black Villain Was Secretly the Most Popular Character
- 25 “Woke” Films That Used Black Trauma to Humanize White Leads
- Silver Rate Forecast
- Gold Rate Forecast
- Spotting the Loops in Autonomous Systems
- From Bids to Best Policies: Smarter Auto-Bidding with Generative AI
- Celebs Who Narrowly Escaped The 9/11 Attacks
- 22 Films Where the White Protagonist Is Canonically the Sidekick to a Black Lead
- Can AI Lie with a Picture? Detecting Deception in Multimodal Models
2026-03-04 23:04